linagliptin/metformin (Jentadueto®)

Reference No. 2446

Publication date:

14/08/2014

Appraisal information

linagliptin/metformin (Jentadueto®) 2.5 mg/1000 mg film-coated tablet
linagliptin/metformin (Jentadueto®) 2.5 mg/850 mg film-coated tablet

Company:	Boehringer Ingelheim Ltd
BNF category:	Endocrine system
NMG meeting date:	18/06/2014
AWMSG meeting date:	16/07/2014

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	2114
Ratification by Welsh Government:	13/08/2014

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.

Final Appraisal Recommendation (FAR)

Download

linagliptin-metformin (Jentadueto) 2446 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

linagliptin-metformin (Jentadueto) 2446 ASAR

Clinical Expert (CE) Summary

Download

linagliptin-metformin (Jentadueto) 2446 CE Summary